Merck’s Ervebo gets its first regulatory greenlight. A decision from the US Food and Drug Administration is expected in the next few months.

TAK-003 appears to avoid the safety issues seen with an existing vaccine, but experts say a longer evaluation is needed.

Tested in patients with the latent form of tuberculosis, the vaccine prevented the development of the active form of infection in 50 percent more individuals compared with unvaccinated patients.

The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the globe.

Antibiotics disrupt the immune response to the influenza vaccine in people who haven’t recently had exposure to the virus or immunization.

Mathematical models reveal that current vaccination rates in Texas schools could pave the way for the virus to spread to hundreds of people.

Researchers aim to deploy the trial in neighboring Democratic Republic of Congo, which has been ravaged by Ebola for a year.

See how a computational pipeline uses next-generation sequencing data to identify genetic alterations that produce cancer-specific antigens.

The devastating outbreak of the disease that has led to millions of pig deaths in East Asia has intensified efforts to develop a vaccine quickly, but the virus presents several challenges that are yet to be overcome.